Download PDF
Thromb Haemost 1995; 74(02): 680-685
DOI: 10.1055/s-0038-1649797
Orignal Articles
Coagulation
Schattauer GmbH Stuttgart

Generation and Mechanism of Action of a Potent Inhibitor of Factor XIII Function

G L Reed
Massachusetts General Hospital, Harvard Medical School, and Harvard School of Public Health, Boston MA, USA
,
D Lukacova
Massachusetts General Hospital, Harvard Medical School, and Harvard School of Public Health, Boston MA, USA
› Author Affiliations
Further Information

Publication History

Received 20 September 1994

Accepted after revision 28 February 1995

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Although known to play a critical role in thrombosis, the precise role of factor XIII in other processes like wound healing and gestation remains to be elucidated. Because a specific, potent inhibitor could help define the function of factor XIII in these processes, or determine the potential benefits of factor XIII suppression in thrombotic disease, we have derived and characterized a monoclonal antibody inhibitor of factor XIII activation. This immunoinhibitor, 9C11, reacts specifically with both plasma and platelet forms of factor XIII. When added to human plasma, either as whole immunoglobulin or as Fab fragments, 9C11 completely prevented thrombin-activated factor XIII activity with small molecular weight substrates like 14C-putrescine. In addition, when clotted with plasma, 9C11 ablated the gamma chain crosslinking of fibrin catalyzed by factor XIII and markedly accelerated the fibrinolysis of plasma clots by urokinase. Studies of the mechanism of action showed that 9C11 inhibited the cleavage and activation of factor XIII by thrombin, but did not affect the catalytic function of previously activated factor XIII. Although it inhibited thrombin activation, experiments indicated that it bound comparably to both factor XIII zymogen and the thrombin-cleaved zymogen, and did not bind to the thrombin cleavage site of the molecule. Taken together these experiments indicated that 9C11 acted as an inhibitor of the thrombin cleavage and activation of the factor XIII A-subunit. Its potency and specificity make it a useful agent for studying thrombin-activatable factor XIII function in biological systems.

 

  • References

  • 1 Lorand L. Activation of blood coagulation factor XIII. Ann N Y Acad Sci 1986; 485: 144-58
    CrossrefPubMedGoogle Scholar
  • 2 Chen R, Doolittle RT. Isolation, characterization and location of a donor- acceptor unit from cross-linked fibrin. Proc Natl Acad Sci USA 1970; 66: 472-479
    CrossrefPubMedGoogle Scholar
  • 3 Pisano JJ, Bronzert TJ, Peyton MP, Finlayson JS. €-(γ-Glutamyl) lysine cross-links: determination in fibrin from normal and factor XIII-deficient individuals. Ann N Y Acad Sci 1972; 202: 98-113
    CrossrefPubMedGoogle Scholar
  • 4 Tamaki T, Aoki N. Cross-linking of α2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim Biophys Acta 1981; 661: 280-286
    CrossrefPubMedGoogle Scholar
  • 5 Mosher DF. Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor. J Biol Chem 1975; 250: 6614
    PubMedGoogle Scholar
  • 6 Lorand L, Jacobson A. Accelerated lysis of blood clots. Nature 1962; 195: 911-912
    PubMedGoogle Scholar
  • 7 Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human factor XIII from plasma and platelets: Molecular weights, subunit structure, proteolytic activation and crosslinking of fibrinogen and fibrin. J Biol Chem 1973; 248: 1395-1407
    PubMedGoogle Scholar
  • 8 Kicsselbach TH, Wagner RH. Demonstration of factor XIII in human megakaryocytes by a fluorescent antibody technique. Ann New York Acad Sci 1972 202: 318-328
    PubMedGoogle Scholar
  • 9 Muszbek L, Adany R, Szegedi G, Polgar J, Kavai M. Factor XIII of blood coagulation in human monocytes. Thromb Res 1985; 37: 401-410
    CrossrefPubMedGoogle Scholar
  • 10 Henriksson P, Becker S, Lynch G, McDonagh J. Identification of intracellular factor XIII in human monocytes and macrophages. J Cin Invest 1985; 76: 528-534
    CrossrefPubMedGoogle Scholar
  • 11 Bohn VH, Schwick HG. Isolierung and Charakterisierung eines fibrinstabilisierenden Faktors aus menschlichen Plazenten. Arzneim Borsch (Drug Res.) 1971; 21: 1432-1439
    PubMedGoogle Scholar
  • 12 Sakata Y, Aoki N. Cross-linking of α2-plasmin inhibitor to fibrin by fibrinstabilizing factor. J Clin Invest 1980; 65: 290-297
    CrossrefPubMedGoogle Scholar
  • 13 Francis CW, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. Blood 1988; 71: 1361-1365
    PubMedGoogle Scholar
  • 14 Reed GL, Matsueda GR, Haber L. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking ofα2-antiplasmin to fibrin. Thromb Haemost 1992; 68: 315-320
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Bockenstedt P, McDonagh J, Handin Rl. Binding and covalent crosslinking of purified von Willebrand factor to native monomeric collagen. J Clin Invest 1986; 78: 551-556
    CrossrefPubMedGoogle Scholar
  • 16 Sane DC, Moser TL, Pippen AM, Parker CJ, Achyuthan KE, Greenberg CS. Vitronectin is a substrate for transglutaminases. Biochem Biophys Res Comm 1988; 157: 115-120
    CrossrefPubMedGoogle Scholar
  • 17 Asijee GM, Muszbek L, Kappelmayer J, Polgar J, Horvath A, Sturk A. Platelet vinculin: a substrate of activated factor XIII. Biochim Biophys Acta 1988; 954: 303-8
    CrossrefPubMedGoogle Scholar
  • 18 Barry EL, Mosher DF. Binding and degradation of blood coagulation factor XIII by cultured fibroblasts. J Biol Chem 1990; 265: 9302-9307
    PubMedGoogle Scholar
  • 19 Board PG, Losowsky MD, Miloszweski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev 1993; 7: 229-242
    CrossrefPubMedGoogle Scholar
  • 20 Lukacova D, Matsueda GR, Haber E, Reed GL. Inhibition of factor XIII activation by an anti-peptide monoclonal antibody. Biochemistry 1991; 30: 10164-10170
    CrossrefPubMedGoogle Scholar
  • 21 Galfre G, Howe SC, Milstein C, Butcher GW, Howard JC. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature 1977; 266: 680-685
    CrossrefPubMedGoogle Scholar
  • 22 Mudgett-Hunter M, Anderson W, Haber E, Margolies MN. Binding and structural diversity among high-affinity monoclonal anti-digoxin antibodies. Mol Immunol 1985; 22: 477-488
    CrossrefPubMedGoogle Scholar
  • 23 Fraker PJ, Speck JJ. Protein and cell membrane inclinations with sparingly soluble ehloramide 1,3,4,6-tetraehloro-3a,6a-diphenylglyeouricil. Biochem Biophys Res Commun 1978; 80: 849-857
    CrossrefPubMedGoogle Scholar
  • 24 Lorand L, Campbell-Wilkes VK, Cooperstein L. A filter paper assay for transamidating enzymes using radioactive amine substrates. Anal Biochem 1972; 50: 623-631
    CrossrefPubMedGoogle Scholar
  • 25 Reed GL. Generation of species-specific, rat monoclonal antibodies that bind to the kappa chain of mouse immunoglobulin. J Immunol Meth 1992; 147: 111-117
    CrossrefPubMedGoogle Scholar
  • 26 Reed III GL, Matsueda GR, Haber L. Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits α2-antiplasniin. Proe Natl Acad Sci USA 1990; 87: 1114-1118
    CrossrefPubMedGoogle Scholar
  • 27 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5
    CrossrefPubMedGoogle Scholar
  • 28 Kyhse-Andcrsen J. Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. J Biochem Biophys Methods 1984; 10: 203-209
    CrossrefPubMedGoogle Scholar
  • 29 Lukacova D, Reed GL. Single step purification of platelet factor XIII using an immobilized factor XIII a-subunit monoclonal antibody. Thromb Haemost 1993; 69: 397-400
    PubMedGoogle Scholar
  • 30 Janus TJ, Lewis SD, Lorand L, Shafer JA. Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen. Biochemistry 1983; 22: 6269-6272
    CrossrefPubMedGoogle Scholar
  • 31 Greenberg CS, Achyuthan KE, Miraglia CC, Dobson JV. Regulation of thrombin cleavage of plasma factor XIII bound to fibrin. Ann N Y Acad Sci 1986; 485: 141-143
    PubMedGoogle Scholar
  • 32 Naski MC, Lorand L, Shafer JA. Characterization of the kinetic pathway for fibrin promotion of u-thrombin-catalyzed activation of plasma factor XIII. Biochemistry 1991; 30: 934-941
    CrossrefPubMedGoogle Scholar
  • 33 Lorand L. Hemorrhagic disorders of fibrin-stabilization. In: Haemostasis: Biochemistry, Physiology and Pathology. Ogston D, Bennett B. (eds) London: John Wiley; 1977. p 405
    Google Scholar
  • 34 Lopaciuk S, Bykowska K, McDonagh JM, McDonagh RP, Yount WJ, Fuller CR, Cooperstein L, Gray A Jr, Lorand L. Difference between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. J Clin Invest 1978; 61: 1196-1203
    CrossrefPubMedGoogle Scholar
  • 35 Lorand L, Velasco PT, Rinne JR, Amare M, Miller LK, Zucker ML. Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system. Proc Natl Acad Sci USA 1988; 85: 232-236
    CrossrefPubMedGoogle Scholar
  • 36 Freyssinet JM, Lewis BA, Holbrook JJ, Shore JD. Protein-protein interactions in blood clotting: the use of polarization of fluorescence to measure the dissociation of plasma factor XHIa. Biochem J 1978 169: 403-410
    PubMedGoogle Scholar
  • 37 Parameswaran KN, Velasco PT, Wilson J, Lorand L. Labeling of e-lysine crosslinking sites in proteins with peptide substrates of factor XHIa and transglutaminase. Proc Natl Acad Sci USA 1990; 87: 8472-8475
    CrossrefPubMedGoogle Scholar
  • 38 Shebuski RJ, Sitko GR, Claremon DA, Baldwin JJ, Remy DC, Stern AM. Inhibition of factor XHIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood 1990; 75: 1455-1459
    PubMedGoogle Scholar